CLINICAL ANALYSIS OF THE COMPLEX WORLD OF INHERITED MULTIPLE AUTOIMMUNITY by Colarusso, Gloria
                                    	  	   	  DOTTORATO	  DI	  RICERCA	  IN	  	  SCIENZE	  BIOMEDICHE	  dell’ETA’	  EVOLUTIVA	  	   CICLO	  XXVI	  	  	  	   	  COORDINATORE	  Prof.	  Persio	  Dello	  Sbarba	  
 	  
CLINICAL	  ANALYSIS	  OF	  THE	  COMPLEX	  WORLD	  OF	  
INHERITED	  MULTIPLE	  AUTOIMMUNITY	  	  	  	   Settore	  Scientifico	  Disciplinare	  MED/38	  	  	  	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Dottorando	  	   	   	   	  	  Tutore	  	  Dott.ssa	  Gloria	  Colarusso	  	   	   	   	  	  Prof.	  Paolo	  Lionetti	  	  _______________________________	   	   	   	   _____________________________	  
	   	   	  	  
Coordinatore	  Prof.	  Persio	  Dello	  Sbarba	  	  	   _______________________________	  	  	   	  Anni	  2011/2013	  	  




MATERIAL	  AND	  METHODS	  ................................................................................. 10	  
CLINICAL	  AND	  IMMUNOLOGICAL	  PRESENTATION	  OF	  PATIENT	  ............ 13	  
IPEX .....................................................................................................13 
      Clinical and Laboratory features ..................................................13 
      Treatment and outcome ..................................................................14 
      Molecular analysis ..........................................................................15 
IPEX-LIKE ..........................................................................................15 
IPEX-like early onset ..........................................................................16 
       Clinical features ............................................................................16 
       Laboratory results .........................................................................17 
      Treatment and outcome ..................................................................18 
     Molecular analysis ...........................................................................19 
IPEX-like delayed onset .....................................................................20 
       Clinical features ............................................................................20 
       Laboratory results .........................................................................21 
      Treatment and outcome .................................................................22 
     Molecular analysis ...........................................................................23 
Multiple autoimmune disease without diarrhoea ............................23 
DISCUSSION	   ............................................................................................................ 24	  
TABLE	  (I,	  II,	  IIIA,	  IIIB,)	  AND	  FIGURES	  (2,	  3) ........................................................... 31	  
BIBLIOGRAPHY	  ........................................................................................................... 37	  
	   2	  
ABSTRACT	  
	  
IPEX	   is	   characterized	   by	   early-­‐onset	   severe	   autoimmune	   enteropathy,	  eczema	  and	  endocrinopathy.	  Increasing	  number	  of	  patients	  affected	  by	  multiple	   autoimmunity	   resembling	   IPEX,	   without	   FOXP3	   mutations	  have	   contributed	   to	  define	   an	   IPEX-­‐like	  phenotype.	  We	   set	   to	   identify	  clinical	  and	  laboratory	  indicators	  to	  better	  define	  this	  disease	  spectrum.	  Clinical	  characteristics	  of	  about	  76	  patients	  with	  immunodysregulation	  referred	  to	  us	  for	  suspected	  IPEX	  syndrome	  were	  analyzed:	  only	  16	  had	  
FOXP3	   mutations	   and	   in	   selected	   patients	   STAT5b,	   CD25,	   STAT1	   and	  IL10	   deficiency	   (IL10RA,	   IL10RB,	   IL10)	   have	   been	   ruled	   out.	   Immune	  mediated	  enteropathy,	  frequently	  associated	  with	  failure	  to	  thrive,	  was	  the	   key	   clinical	   feature.	   In	   patients	   without	   enteropathy,	  endocrinopathy	   and	   cytopenias	   are	   the	   main	   clinical	   manifestations.	  The	   age	   of	   onset	   is	   diverse:	   a	   group	   of	   patients	   presents	   diarrhoea	  within	   the	   first	   year	   of	   life	   and	   behave	   similarly	   to	   the	   IPEX	   cohort,	  another	   group	   had	   a	   delayed	   onset	   characterized	   by	   multiple	  autoimmune	  disease	  (skin	  and	  endocrinopathy	  being	  less	  predominant	  than	   to	   autoimmune	   cytopenias	   and	   infections),	   whilst	   a	   third	   group	  had	   only	   early	   onset	   diarrhoea	   with	   no	   other	   symptoms	   associated	  (IBD-­‐like?).	   Elevated	   IgE	   and	   dysgammaglobulinemia	   are	   often	  reported.	  	  
Outputs	   from	   this	   study	   define	   disease	   subgroups	   facilitating	   precise	  molecular	   studies	   in	   order	   to	   better	   understand	   and	   delineate	   the	  mechanisms	  of	  tolerance	  failure	  in	  patients	  with	  complex	  autoimmune	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INTRODUCTION	  
	  
Immune	   dysregulation,	   polyendocrinopathy,	   enteropathy,	   X-­‐linked	  (IPEX,	  OMIM	  304790)	  syndrome	   is	  a	   rare	  monogenic,	   life-­‐threatening,	  congenital	   immunodeficiency	   caused	   by	   defective	   peripheral	   immune	  tolerance,	   originally	   described	   by	   Powell	   et	   al.	   in	   1982	   [1].	   The	  phenotype	   is	   characterized	   by	   early-­‐onset	   severe	   autoimmune	  enteropathy	   with	   failure	   to	   thrive,	   eczematous	   skin	   rash	   and	  endocrinopathy,	   usually	   insulin-­‐dependent	   diabetes	   mellitus	   (IDDM).	  Less	  common	  manifestations	  include	  immune	  thrombocytopenia	  (ITP),	  autoimmune	  haemolytic	   anaemia	   (AIHA),	   thyroiditis	   and	  nephropathy	  [2,	   3].	   Moreover,	   most	   of	   the	   patients	   suffer	   from	   infections,	   ranging	  from	   moderate	   recurrent	   infections	   of	   the	   upper	   respiratory	   or	  gastrointestinal	   tract,	   to	   invasive	   life-­‐threatening	   episodes,	   including	  sepsis	   and	   meningitis	   [4–6].	   It	   is	   still	   unclear	   if	   the	   significantly	  increased	  susceptibility	  to	  infections	  is	  related	  to	  their	  genetic	  defect	  or	  if	  this	  is	  secondary	  to	  other	  clinical	  features,	  such	  as	  decreased	  barrier	  function	   of	   the	   skin	   and	   gut,	   or	   to	   immunosuppressive	   therapy.	  Laboratory	   findings	   include	   increased	  IgE	  and	  eosinophil	  values	  and	  a	  variety	   of	   autoantibodies,	   which	   usually	   correlates	   with	   signs	   of	  pathology	   in	   the	   target	   organs;	   no	   main	   immunological	   defects	   have	  been	  associated	  with	  IPEX.	  
IPEX	   is	   caused	   by	   mutations	   in	   the	   forkhead	   box	   protein	   3	   (FOXP3)	  gene,	   located	   on	   chromosome	   Xp11.23	   [2,7],	   which	   encodes	   a	   DNA	  binding	   protein	   that	   is	   a	   member	   of	   the	   forkhead	   (FKH)	   family	   of	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transcription	   factors	   critical	   for	   the	   development	   and	   function	   of	  natural	   CD4+CD25+FOXP3+regulatory	   T	   cells	   (nTreg),	   that	   suppress	  the	  activation	  of	  peripheral	  auto-­‐reactive	  T	  cells	  [4,5].	  In	  addition	  to	  the	  loss	  of	  suppressive	  function,	  FOXP3	  mutations	  seems	  also	  cause	  a	  hight	  instability	  of	  the	  Treg	  cell	  compartment	  with	  a	  marked	  shift	  to	  the	  Th17	  cell	  phenotype	  of	  bona	  fide	  nTreg	  cells	  [8],	  that	  means	  an	  inflammation-­‐driven	   conversion	   from	   a	   regulatory	   to	   an	   effector	   (i.e.,IL-­‐17-­‐producing)	   phenotype	   of	   mutated	   Treg	   cells,	   which	   may	   directly	  contribute	  to	  the	  autoimmune	  damage	  in	  the	  target	  organs.	  	  
FOXP3	   consists	   of	   11	   exons	   that	   encode	   a	   protein	   of	   431	   amino	   acids	  expressed	   primarily	   in	   lymphoid	   tissues	   (thymus,	   spleen,	   and	   lymph	  nodes),	   particularly	   in	   CD4+CD25+	   regulatory	   T	   cells.	   The	   FOXP3	  protein	  has	  several	  specific	  regions	   including	  a	  proline-­‐rich	  domain	  at	  the	   N-­‐terminus,	   a	   zinc	   finger	   and	   leucine	   zipper	   (both	   conserved	  structural	  motifs	  involved	  in	  protein/protein	  interaction)	  in	  the	  central	  portion,	   and	   a	   forkhead	   DNA-­‐binding	   domain	   at	   the	   C-­‐terminus.	   The	  severity	   of	   the	   disease	   does	   not	   always	   correlate	  with	   the	   absence	   of	  protein	  expression.	  Gene	  analysis	  revealed	  missense	  mutations	  (usually	  point	  mutations)	   in	   the	  majority	   of	   affected	   individuals,	   resulting	   in	   a	  normal	  or	  reduced	  level	  of	  expression	  of	  mutant	  protein	  with	  a	  normal	  percentage	  of	  CD4+CD25+FOXP3+	  T	  cell	  detected	  by	  flow	  cytometry	  in	  the	   peripheral	   blood.	   Therefore,	   in	   IPEX	  patients	   FOXP3mutTreg	   cells	  are	  physically	  present	  but	  functionally	  impaired,	  and	  this	  is	  considered	  the	  primary	  cause	  of	  autoimmunity	  in	  IPEX.	  	  
IPEX	   is	   a	   severe	   condition	   requiring	   a	   prompt	   treatment	   with	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corticosteroids	   and	   immunosuppressive	   drugs	   [5,	   9],	   but	   only	  hematopoietic	  stem	  cell	   transplantation	  (HSCT)	  can	  offer	  a	  permanent	  cure	  [10,	  11].	  
Increasingly,	   patients	   affected	   by	   multiple	   autoimmune	   diseases	  resembling	  IPEX,	  without	  FOXP3	  mutations,	  have	  contributed	  to	  define	  an	  IPEX-­‐like	  phenotype.	  Two	  other	  proteins	  related	  to	  FOXP3	   function	  has	  been	  recognized	  so	  far:	  IL-­‐2R	  alpha	  (CD25)	  and	  STAT5b.	  	  
The	  IL-­‐2	  receptor	  is	  formed	  by	  the	  α	  (CD25),	  β	  (CD122)	  and	  common	  γ-­‐chain	   (CD132)	   subunits,	   and	   plays	   a	   vital	   role	   in	   maintaining	   the	  immune	  system.	  CD25,	  constitutively	  expressed	  at	  high	   levels	  by	  Treg,	  binds	   exclusively	   IL-­‐2.	   Therefore	   Treg	   are	   able	   to	   respond	   to	   low	  concentration	  of	  IL-­‐2	  at	  all	  times,	  promoting	  the	  maintenance	  of	  FOXP3	  expression	   by	   amplifying	   IL-­‐2	   signaling	   in	   a	   STAT5-­‐dependent	   way	  [12].	  	  
Three	  unrelated	  patients	  with	  CD25	  deficiency	  have	  been	   reported	   so	  far	   [13-­‐16].	   	   They	   presented	   with	   clinical	   features	   resembling	   IPEX	  patients,	  but	  with	  an	  increased	  susceptibility	  to	  viral	  infections	  (mainly	  chronic	   CMV	   infection)	   and	   developed	   autoantibodies,	  hepatosplenomegaly,	   lymphadenopathy	   and	   lymphocytic	   infiltrates	   in	  various	   organs.	   Notably,	   CD25	   expression	   on	   the	   surface	   of	   patient’s	  CD4+	  T	  cells	  was	  absent.  
STAT5b	  is	  a	  common	  downstream	  effector	  of	  various	  cytokines	  (IL-­‐2,	  -­‐4,	   -­‐7,	   -­‐9,	   -­‐13,	   -­‐15,	   -­‐21),	   growth	   hormone	   (GH)	   [17],	   erythropoietin,	  thrombopoietin,	   and	   granulocyte	   colony-­‐stimulating	   factor	   signaling	  molecules	   [18].	   STAT5b	   is	   a	   member	   of	   the	   signal	   transducer	   and	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activator	   of	   transcription	   family	   of	   proteins,	   which	   regulate	   gene	  transcription	   in	   response	   to	   various	   cytokines	   and	   growth	   factors.	  
STAT5b	   is	   a	   critical	   transducer	   of	   interleukin-­‐2-­‐mediated	   signals	  required	  to	  sustain	  FOXP3	  expression	  in	  Treg	  and	  to	  maintain	  Treg	  cells	  themselves	   [19,	   20].	   	   Ten	   cases	   of	   STAT5b	  deficiency,	   inherited	   as	   an	  autosomal	   recessive	   disorder	   have	   been	   reported	   [21-­‐23]	   Affected	  individuals	  present	  with	  severe	  growth	  failure	  after	  birth	  with	  normal	  levels	  of	   serum	  GH	  and	   low	   levels	  of	   IGF-­‐1	  and	   IGFBP-­‐3,	   autoimmune	  disease,	  chronic	  infections,	  chronic	  lung	  disease,	  eczema	  and	  diarrhoea.	  Immunological	   work	   up	   revealed	   modest	   lymphopenia,	   low	   T	   cell	  counts	   (CD4+,	   CD8+),	   low	   NK	   cells	   and	   Treg	   dysfunction.	   In	   mice,	  deletion	   of	   STAT5a/b	   in	   CD4+	   T	   cells	   results	   in	   marked	   reduction	   of	  Foxp3+	   and	  CD4+CD25+	   cells	   in	   both	   thymus	   and	   periphery;	   humans	  with	   STAT5a/b	   mutations	   display	   immune	   dysregulation	   associated	  decreased	  CD25	  and	  FOXP3	  expression	  [24,	  25].	  
Moreover,	  in	  this	  contest,	  IL-­‐10	  and	  TGF-­‐	  β	  have	  also	  an	  important	  role	  in	   immune	   homeostasis	   and	   are	   secreted	   both	   by	   dendritic	   cells	   and	  Tr1	  cells,	  a	  subtype	  of	  regulatory	  T	  cells	  which	  do	  not	  express	  CD25,	  nor	  FOXP3	  [26].	  Glocker	  et	  al	   [27],	  postulate	   that	  mutations	  affecting	   IL10	  and	   IL-­‐10	   receptor	   (IL10R1	   and	   IL102)	   abrogate	   IL-­‐10–mediated	  immunomodulatory	   signaling,	   strongly	   associated	   with	  hyperinflammation	  of	  the	  intestine.	  Patients	  presented	  with	  early-­‐onset	  enterocolitis	   (within	   the	   first	   year	   of	   age)	   characterized	   by	   an	  aggressive	   course	   with	   recurrent	   abscesses	   and	   entero-­‐cutaneous	  fistula,	   follicular	  rash	  and	  recurrent	  infections	  that	  were	  thought	  to	  be	  primarily	   associated	   with	   immune	   suppression.	   Immune	   parameters	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including	  serum	  immunoglobulins,	  lymphocyte	  subsets,	  and	  neutrophil	  oxidative	  burst	  seems	  to	  be	  normal.	  Alterations	  in	  IL10	  and	  its	  receptor	  genes	  would	  be	  associated	  with	  specific	  IPEX-­‐like	  phenotypes.	  	  
Recently	   a	   gain	   of	   function	   mutations	   in	   STAT1,	   a	   key	   transcription	  factor	   mediating	   IFN-­‐α	   /β	   signaling,	   has	   been	   found	   in	   patients	  presenting	  with	  multiple	  autoimmune	  disease,	  chronic	  candidiasis	  and,	  sometimes,	  cerebral	  aneurism	  [28].	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MATERIAL	  AND	  METHODS	  
	  
Patients	  
Blood	   samples	   from	   113	   patients	   with	   immunodysregulation,	   coming	  from	   different	   countries,	   were	   referred	   to	   the	   NEUROFARBA	  Department,	   Section	   of	   Child's	   Health,	   University	   of	   Florence,	   Italian	  Study	  Group	  of	   IPEX,	   for	  genetic	  analysis	   from	  2004	  to	  2013.	  Patient’s	  clinical	   and	   immunological	   information	   were	   collected	   from	   the	  referring	   physician	   who	   filled	   out	   a	   registration	   form.	   Data	   from	   14	  patients	   were	   unavailable	   or	   lacking;	   clinical	   presentation	   in	   17	  subjects	  was	  not	  consistent	  with	  IPEX	  disease.	  6	  patients	  had	  a	  different	  diagnosis	  at	   follow	  up	  update.	   In	   this	   study	  data	   from	  76	  patients	   (56	  male,	  20	  female)	  were	  analysed.	  	  The	   clinical	   diagnosis	   of	   IPEX/IPEX-­‐like	   syndrome	   was	   based	   on	   the	  presence	   of	   severe	   enteropathy	   together	   with	   at	   least	   one	   of	   the	  following	   characteristics:	   (a)	   IDDM	   or	   thyroiditis;	   (b)	   severe	   eczema;	  (c)	   specific	   autoantibodies	   (anti-­‐insulin,	   IA-­‐2,	   GAD,	   enterocytes);	   (d)	  cytopenias;	   (e)	   other	   autoimmune	   manifestations	   (hypothyroidism,	  polyarthritis,	   vitiligo,	   etc).	   A	   small	   group	   of	   patients	   without	  enteropathy	   was	   included	   in	   the	   study	   because	   of	   the	   complex	  autoimmunity	  clinical	  pattern.	  	  
Clinical	   and	   immunological	   data,	   were	   analysed	   retrospectively,	   and	  included	   age	   of	   onset;	   features	   of	   autoimmune	   enteropathy	   including	  intestinal	  biopsy	  results;	  evidence	  of	  endocrinopathy	  such	  as	  IDDM	  and	  thyroiditis;	   cutaneous	   symptoms;	   haematological	   abnormalities	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including	   AIHA,	   ITP	   and	   neutropenia;	   type	   of	   infections;	   renal	  involvement;	   lymphadenopathy	   and/or	   hepatosplenomegaly;	   general	  examination.	  	  
Gut	   biopsies,	   when	   available,	   were	   evaluated	   to	   differentiate	   patients	  with	   autoimmune	   enteropathy	   with	   villous	   atrophy	   (GvHD-­‐like	  enteropathy)	  from	  patients	  with	  other	  gut	  damage	  (celiac-­‐like	  disease,	  enteropathy	  with	  autoantibodies)	  [30].	  
Molecular	  analysis	  
Genomic	  DNA	  was	  extracted	   from	  peripheral	  blood	  mononuclear	   cells	  (PBMCs)	  using	  the	  QIAamp	  DNA	  Blood	  Mini	  Kit	   (Qiagen,	  Valencia,	  CA)	  according	   to	   the	  manufacturer's	   recommendations.	   The	   entire	   coding	  sequence	  (including	  exon-­‐intron	  junctions)	  of	  the	  genes	  FOXP3,	  IL2Ra,	  IL10/RA/RB,	  STAT5b,	  was	  amplified	  using	  standard	  polymerase	  chain	  reaction	   (PCR)	   conditions	   using	   a	   different	   Tm:	   FOXP3	   60°C,	   IL2Ra	  55°C,	   IL10/RA/RB	  58°C,	   STAT5b	  58°C.	   PCR	  products	  were	   sequenced	  using	  the	  BigDye	  Terminator	  Cycle	  Sequencing	  Kit	  (Applied	  Biosystems,	  Foster	   City,	   CA)	   on	   an	   automated	   ABI	   PRISM	   3130	   Genetic	   Analyzer	  (Applied	   Biosystems)	   and	   compared	   to	   reported	   reference	   cDNA	  sequence.	  
The	   Laboratory	   of	   Clinical	   Infectious	   Diseases,	   National	   Institutes	   of	  Allergy	  and	  Infectious	  Diseases,	  National	  Institutes	  of	  Health,	  Bethesda	  performed	  STAT1	  analysis	  [28].	  
In	   69/76	   patients	   (13	   female,	   56	  male)	   the	   coding	   regions,	   including	  intron/exon	  junctions,	  of	  FOXP3	  gene	  were	  analysed	  and	  the	  diagnosis	  of	   IPEX	   syndrome,	   based	   on	   FOXP3	   mutation,	   was	   confirmed	   in	   16	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patients.	   Female	  patients	  were	   screened	   for	   IPEX	  at	   the	  beginning	   for	  understanding	   the	  possibility	   of	   X-­‐inactivation.	   Those	  with	   the	   typical	  clinical	   and	  pathologic	   features	  of	   IPEX,	  negative	  FOXP3	   gene	   analysis	  or	  female	  patients,	  were	  classified	  as	  IPEX-­‐like.	  	  
CD25	  was	  investigated	  in	  26	  patients	  and	  3	  mutations	  were	  identified.	  	  
STAT5b	   and	   IL10,	   IL10	   RA,	   IL10RB	   genes	   were	   analysed	   in	   15	   and	   3	  patients	  respectively,	  but	  no	  mutations	  were	  found.	  	  


















Clinical	  and	  laboratory	  features	  
IPEX	   was	   diagnosed	   in	   16	   out	   of	   69	   patients	   analysed	   for	   FOXP3	  mutation	   [table	   II].	   Unfortunately	   clinical	   information	   concerning	   two	  siblings	  was	   not	   available.	   Enteropathy	   is	   the	  main	   clinical	   feature	   of	  presentation	  among	  IPEX	  subjects.	  Early	  onset	  severe	  watery	  diarrhoea	  was	   present	   in	   11/14	   (range	   of	   onset:	   0-­‐5	   months);	   small	   bowel	  biopsies	  were	  compatible	  with	  patterns	  of	  autoimmune	  enteropathy	  in	  all.	  
3/14	   presented	   an	   atypical	   IPEX	   syndrome:	   one	   developed	   delayed	  onset	  diarrhoea	   (11	  years	  old)	  with	   acute	   enterocolitis	   and	  ulcerative	  mucosa	   at	   gut	   biopsy;	   another	   one	   had	   failure	   to	   thrive	   since	   birth	  without	   diarrhoea	   with	   endoscopic	   appearance	   of	   ulcerative,	  oedematous	   and	   hyperaemic	   gastric	   mucosa;	   the	   last	   one	   was	  diagnosed	   because	   of	   a	   sibling	   affected,	   but	   he	   did	   not	   present	   any	  clinical	  symptoms	  so	  far.	  
Moderate	   to	   severe	   eczema	   affecting	   mainly	   trunk,	   face	   and	   limbs,	  occurred	  in	  12/14	  patients	  within	  three	  months	  of	  life.	  
Contrary	  to	  what	  previously	  described,	  only	  2/14	  had	  neonatal	   IDDM;	  no	  other	  endocrinopathies	  were	  mentioned.	  AIHA	  and	  ITP	  were	  present	  in	   2	   patients	   respectively.	   Renal	   calculi	   were	   found	   in	   one	   patient,	  probably	   as	   a	   consequence	   of	   dehydration	   and	   electrolyte	   alterations.	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One	   experienced	   nephritic	   syndrome,	   one	   had	   acute	   tubular	   necrosis	  and	   one	   developed	   clear	   cell	   renal	   carcinoma.	   Lymphadenopathy	   and	  splenomegaly	  were	  observed	  in	  2	  and	  4	  patients	  respectively.	  
Before	   immunosuppressive	   treatment	   was	   started,	   serious	   infection	  occurred	  in	  7/14	  patients:	  4	  had	  septic	  episodes,	  2	  had	  osteomyelitis,	  2	  patients	  were	  admitted	  to	  Paediatric	  Intensive	  Care	  Unit	  for	  respiratory	  distress.	  Upper	   respiratory	   tract	   infections	  were	   present	   in	   almost	   all	  patients.	  	  
Laboratory	   work	   up	   showed	   increased	   IgE	   levels	   in	   11/14	   patients;	  none	  had	  impaired	  immunological	  results.	  
Treatment	  and	  outcome	  
Treatment	   approach	   was	   mainly	   focused	   on	   limiting	   life-­‐threatening	  gastrointestinal	  symptoms.	  At	  the	  beginning	  patients	  were	  treated	  as	  a	  case	  of	  allergic	  gastro-­‐enteropathy	  and	  different	  kind	  of	  elemental	  milk	  were	  introduced.	  Changing	  of	   feeds	  did	  not	  cause	  any	  improvement	   in	  their	  symptoms	  so	  total	  parenteral	  nutrition	  was	  commenced	  in	  10/14.	  Because	   of	   the	   worsening	   diarrhoea	   and	   not	   gaining	   weight,	  corticosteroids	   first	   (methylprednisolone/prednisone)	   and	  immunosuppressive	   drugs	   after	   (cyclosporine,	   tacrolimus,	   anti-­‐TNFα	  antibody,	   rapamycin,	   mycophenolate)	   were	   introduced	   in	   12/14	  subjects	  in	  different	  steps	  with	  poor	  benefit	  in	  most	  of	  them.	  	  HSCT	  was	  eventually	  performed	  in	  6	  patients.	  	  	  
Two	   siblings	   did	   not	   receive	   any	   treatment	   because	   one	   had	   severe	  diarrhoea	  that	   improved	  within	  the	  first	  year	  of	   life	  and	  the	  other	  one	  enjoy	  good	  health	  until	  now.	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Patients	   are	   all	   alive	   but	   three,	   two	  deceased	  before	  HSCT	  because	   of	  intractable	  diarrhoea	  and	  sepsis,	  one	  after	  HSCT	  because	  of	  sepsis.	  
Molecular	  Analysis	  




IPEX-­‐like	   subjects	   can	  be	  divided	   in	   three	   subgroups:	   the	   first	   (31/60	  patients;	  10	  female,	  21	  male)	  included	  patients	  with	  severe	  enteropathy	  within	  six	  months	  of	  life,	  the	  second	  (22/60	  patients;	  6	  female,	  16	  male)	  comprised	  patients	  with	  a	  delayed	  onset	  (range:	  1-­‐24	  years),	  the	  third	  enclosed	   patients	   with	   multiple	   autoimmune	   manifestations	   except	  diarrhoea	  (7/60	  patients;	  4	  female,	  3	  male)	  [Fig.	  2].	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IPEX-­like	  early	  onset	  
Clinical	  features	  
In	   this	   cohort	   of	   patients	   two	   different	   subgroups	   of	   subjects	   can	   be	  identified:	  those	  with	  only	  gut	  disease	  and	  those	  with	  enteropathy	  and	  multiple	  autoimmununity.	  	  
7/31	   had	   only	   early	   onset	   watery	   diarrhoea	   (range	   of	   onset:	   0-­‐2	  months)	   not	   improving	   after	   changing	   feeds.	   In	   6	   patients	   gut	   biopsy	  showed	  findings	  of	  autoimmune	  enteropathy	  with	  villous	  atrophy.	  
24/31	  presented	  with	   severe	  diarrhoea	  within	   six	  months	  of	   age.	  Gut	  biopsy	  showed	  GvHD	  enteropathy	  in	  19/24;	  eosinphilic	  colitis	  in	  2/24;	  the	   other	   3	   patients	   had	  moderate	   to	   severe	   chronic	   inflammation	   of	  mucosa.	  Most	   of	   them	   (20/24)	   had	   difficulties	   in	   gaining	  weight	  with	  consequent	  failure	  to	  thrive.	  Cutaneous	  involvement	  with	  eczema	  with	  varying	   degrees	   of	   severity	   was	   present	   in	   16/24	   patients;	   only	   2	  subjects	   had	   alopecia	   and	   one	   developed	   pemphigus	   bullous.	   	   A	   red	  nodular	   rash	   confluent	   with	   red	   lumpy	   areas	   was	   observed	   in	   one	  patient	   since	   the	   second	   day	   of	   life,	   skin	   biopsy	   showed	   a	   vasculitic	  form	  between	  Lupus	  Eritematosus	  and	  Sweet	  Disease.	  Two	  weeks	  after	  he	  developed	  arthritis	  of	  fingers.	  2	  other	  patients	  experienced	  transient	  arthritis.	   Endocrinopathy	   was	   present	   in	   10/24	   patients:	   IDDM	   and	  autoimmune	   thyroiditis	  were	  evident	   in	  4	  and	  7	  patients	  respectively.	  Among	  them,	  one	  patient	  had	  neonatal	  onset	  of	  both	  diseases,	  other	  2	  subjects	  experienced	  both	  at	  different	  age.	  2	  had	  GH	  deficiency,	   in	  one	  patient	   probably	   due	   to	   hypophysitis.	   Autoimmune	   cytopenias	   were	  manifested	  at	  different	  age	  in	  11/24	  patients:	  7	  had	  AIHA,	  5	  had	  ITP,	  4	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had	   autoimmune	   neutropenia.	   Among	   them,	   two	   patients	   developed	  cytopenia	   affecting	   all	   three-­‐cell	   lines.	   Autoimmune	   hepatitis	   was	  diagnosed	   in	   4/24;	   epatosplenomegaly	   was	   evidenced	   in	   2;	  epatomegaly	  and	  splenomegaly	  alone	   in	  1	  and	  2	  subjects	  respectively.	  Mild	   lymphadenopathy	  was	   found	   in	   5/24.	   Two	   Indian	   patients,	  with	  similar	  clinical	  manifestations,	  developed	  tubular	  nephropathy	  (kidney	  biopsy	   non	   available).	   Three	   patients	   had	   psychomotor	   impairment,	  one	   had	   cerebral	   atrophy	   and	   one	   had	   cerebral	   aneurysm	   with	  consequent	  cerebral	  hemorragy.	  	  
Most	  of	   the	  patients	  (21/24)	  suffered	  from	  different	  kind	  of	   infections	  since	   infancy.	   Upper	   respiratory	   tract	   infections	   (mainly	   acute	   otitis	  media)	  were	   described	   in	   9	   patients.	   Low	   respiratory	   tract	   infections	  were	   reported	   in	   10	  patients:	   4	   bronchiolitis	   (RSV	  was	  detected	   in	   2)	  and	  8	  pneumonia	  due	  to	  virus	  and	  bacteria.	  Deep	  infections	  affected	  8	  patients:	   6	   sepsis	   mostly	   as	   a	   consequence	   of	   Staphilococcus	   Aureus,	  
Enterococcal	   and	   Pseudomonas	   Aeruginosa	   infections	   and	   one	   HSV	  encephalitis	   (the	   patient	  was	   limphopenic	   due	   to	   immunosuppressive	  treatment).	  6/24	  had	  gastroenteritis	  and	  3	  had	  perianal	  abscesses.	  CMV	  PCR	  was	  found	  positive	  in	  4	  patients.	  
Laboratory	  results	  
Among	  this	  cohort	  of	  patients,	  immunological	  parameters	  were	  almost	  unremarkable	   with	   the	   exception	   of	   dysgammaglobulinemia	   in	   9	  patients	   and	   lymphopenia	   in	   5	   patients.	   Two	   siblings,	   in	   particular,	  were	  lymphopenic	  with	  good	  distribution	  of	  naïve	  and	  memory	  B	  cells,	  normal	  immunoglobulin	  production	  and	  normal	  in	  vitro	  proliferation	  to	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PHA.	   In	   particular	   the	   oldest	   one	   had	   low	   T	   cell	   number	   (CD3	   414	  cells/microL,	   normal	   range:	   1000-­‐2000	   cells/microL;	   CD4	   185	  cells/microL,	   normal	   range:	   500-­‐1300/microL;	   CD8	   198cells/microL,	  normal	  range:	  300-­‐800/microL;	  NK	  28	  cells/microL,	  normal	  range:100-­‐700/microL)	  and	  slightly	  low	  B	  cell	  number	  (253	  cells/microL,	  normal	  range:	  200-­‐500/microL).	  Interestingly	  them	  both	  did	  never	  receive	  any	  immunosuppressive	   treatment	   during	   their	   life.	   The	   cytokine	   assays,	  performed	   in	   the	   two	   siblings,	   showed	   an	   impaired	   response	   to	   LPS	  (inability	   to	   induce	   IL12	   and	   IL10	   production)	   and	   significantly	  impaired	   production	   of	   TNFα	   and	   IL6.	   These	   results	  would	   suggest	   a	  possible	   defect	   of	   monocyte	   and	   T	   cell	   function,	   with	   TLR	   pathway	  function	  impaired.	  	  
IgE	   levels	   were	   increased	   in	   14	   patients	   (range	   109	   -­‐	   >2000	   kU/l;	  normal	  range	  <100	  KU/l).	  Anti-­‐enterocyte	  antibodies	  were	  positive	  in	  2	  out	   of	   9	   analysed;	   on	   the	   other	   hand	   antinuclear	   antibodies	   and	   anti-­‐smooth	  muscle	  were	  positive	  only	  in	  3	  patients	  respectively.	  	  
Treatment	  and	  outcome	  
Total	   parenteral	   nutrition	   was	   initially	   started	   in	   almost	   half	   of	   the	  patients.	   10	   patients	   received	   IVIG	   for	   both	   hypogammaglobulinemia	  and	   ITP.	   Because	   of	   intractable	   diarrhoea	   and	   autoimmune	  manifestation,	  16	  out	  of	  31	  were	  treated	  with	  corticosteroids	  and	  in	  15	  patients	  immunosuppressive	  therapy	  was	  necessary	  for	  controlling	  the	  disease.	  In	  7	  patients	  HSCT	  was	  performed.	  	  	  
In	   the	   first	   subgroup	   of	   7	   patients,	   2	   died	   because	   of	   intractable	  diarrhoea.	   Two	   patients	   with	   autoimmune	   enteropathy,	   improved	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clinically	  and	  are	  actually	  in	  good	  health;	  another	  one	  gradually	  recover	  after	  bowel	  surgery.	  We	  can	  postulate	  that	  their	  clinical	  and	  histological	  presentation,	  consistent	  with	  IPEX,	  was	  in	  both	  cases	  the	  consequence	  of	   subsequent	   episodes	   of	   infectious	   diarrhoea	   on	   an	   immature	   gut	  setting.	  	  
In	  the	  second	  cohort,	  three	  patients	  died	  at	  13	  months,	  18	  months	  and	  12	  years	  of	  age	  respectively	  in	  consequence	  of	  HSCT	  complications,	  one	  patient	   died	   when	   he	   was	   4	   years	   old	   of	   brain	   hemorrhage	   due	   to	  cerebral	   aneurysm,	   one	   patient	   died	   at	   8	   months	   of	   age	   because	   of	  severe	  diarrhoea	  and	  one	  child	  died	  at	  3	  months	  of	  age	  due	  to	  central	  venous	  catheter	  sepsis.	  
Molecular	  Analysis	  
Among	  the	  31	  patients	  of	   the	   IPEX	   like	  early	  onset	  cohort,	   the	  genetic	  analysis	  of	  CD25	  showed	  the	  presence	  of	  3	  different	  mutations	  in	  three	  patients.	  Two	  of	  them	  are	  single	  nucleotide	  variations	  localized	  in	  exon	  4	   not	   described	   previously	   and	   absent	   in	   a	   group	   of	   200	   control	  chromosomes	   analyzed	   (one	   has	   been	   recently	   published	   [16]).	   Both	  the	  alterations	  lead	  to	  the	  substitution	  of	  a	  single	  aminoacid	  located	  in	  the	  “sushi”	  domain	  of	  the	  protein.	  This	  region	  seems	  to	  be	  fundamental	  for	   IL2-­‐IL2Rα	   interaction,	   thus	   the	   aminoacid	   change	   could	  modify/prevent	   IL2	  binding.	  The	   third	   is	   a	   single	  nucleotide	  variation	  found	   in	   exon	   2	   leading	   to	   an	   aminoacid	   change	   that	   could	   be	  responsible	  of	  the	  alteration	  of	  the	  tertiary	  structure	  of	  the	  receptor.	  
Their	   clinical	   presentation,	   according	   with	   the	   cases	   described	   in	  literature,	   was	   characterised	   by	   intractable	   watery	   diarrhoea	   with	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villous	   atrophy	   within	   the	   first	   month	   of	   life	   associated	   with	   mild	   to	  moderate	   eczema.	   Two	   of	   them	   developed	   autoimmune	  hypothyroidism,	   one	   had	   also	   neonatal	   IDDM.	   CMV	   PCR	   was	   found	  positive	  in	  two	  of	  them,	  as	  in	  most	  of	  the	  patients	  with	  CD25	  deficiency.	  IgE	   level	  was	  normal	  or	   slightly	   increased.	  At	   flow	  cytometry	  analysis	  they	  showed	  absence	  of	  CD25	  cell	  surface	  expression.	  	  
STAT1	   was	   studied	   in	   12	   patients	   and	   one	   had	   a	   gain	   of	   function	  mutation	   (unpublished	   data).	   The	   patient	   had	   multiple	   autoimmune	  manifestations	  and	  died	  because	  of	  brain	  haemorrhage	  due	  to	  cerebral	  aneurism.	  STAT5b	  and	  IL10,	  IL10RA,	  IL10RB	  were	  found	  wild	  type	  in	  6	  and	  3	  patients	  respectively.	  
	  
IPEX-­like	  delayed	  onset	  
Clinical	  features	  
The	  second	  group	  of	  IPEX-­‐like	  patients	  had	  a	  delayed	  onset	  enteropathy	  (range:	  18	  months	  –	  8	  years	  old).	  Diarrhoea	  was	  the	  symptom	  at	  onset	  in	  13	  patients;	  the	  other	  9	  patients	  had	  different	  clinical	  presentations	  characterized	  by	  eczema,	  IDDM	  and	  infectious	  disease.	  
In	   this	   cohort	   half	   of	   the	   patients	   had	   severe-­‐watery	   diarrhoea	   with	  villous	  atrophy	  in	  8	  of	  them	  at	  gut	  biopsy.	  On	  the	  other	  hand,	  11	  out	  of	  22	  had	  a	  moderate	  to	  severe	  diarrhoea	  with	  active	  inflammation	  at	  gut	  biopsy;	  prominent	  eosinophil	  infiltrate	  was	  characteristic	  in	  5	  of	  them.	  Virus	  detection	  on	  specimen	  showed	  CMV	  presence	  in	  3/22,	  and	  HHV6	  and	   EBV	   positive	   in	   2	   patients	   respectively.	   Failure	   to	   thrive	   was	  present	  in	  16	  patients;	  one	  had	  GH	  deficiency.	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Cutaneous	   involvement	   included	   eczematous	   rash	   (10/22),	   alopecia,	  vitiligo	   and	   dystrophic	   nails.	   Endocrinopathy	   was	   the	   second	   most	  frequent	  manifestation,	  as	  it	  was	  present	  in	  11	  subjects:	  7	  had	  IDDM	  (in	  4	   onset	   was	   in	   the	   first	   2	   years	   of	   life)	   and	   6	   had	   autoimmune	  thyroiditis.	  	  
Autoimmune	   cytopenias	   included	   ITP	   and	   AIHA	   in	   5	   patients	  respectively	   (3	   presented	   Evans	   syndrome),	   neutropenia	   in	   2,	   and	  positive	   direct	   Coombs	   test	   alone	   in	   2.	   Hepatic	   involvement	   was	  sporadic:	   3	   patients	   had	   autoimmune	   hepatitis	   and	   3	   subjects	   had	  hepatosplenomegaly.	   Lymphadenopathy	   was	   described	   in	   5.	   Food	  allergy	  with	  skin	  PRICK	  test	  positive	  was	  found	  in	  3	  subjects.	  4	  patients	  out	   of	   22	   suffered	   from	   a	   different	   degree	   of	   nephropathy.	   Arthalgia	  was	  mentioned	  in	  5	  subjects.	  Neurodevelopmental	  delay	  was	  present	  in	  3	  patients	  and	  2	  experienced	  autoimmune	  cerebral	  vasculitis.	  	  
Almost	  all	  patients	  suffered	  from	  infectious	  disease;	  upper	  respiratory	  tract	   infections	  were	   frequently	   reported,	   in	   particular	   5	   patients	   had	  recurrent	   otitis	   media	   with	   Pseudomonas	   Aeruginosa	   detected	   at	  specimen.	  12	  patients	  suffered	  from	  low	  respiratory	  tract	   infections,	  4	  developed	  bronchiectasis.	  6	  had	  deep	  infections:	  Klebsiella	  Pneumoniae,	  
MRSA,	   Candida	  were	   the	  most	   frequent	  microorganisms	   isolated	   from	  cultures.	  CMV	  was	  present	  in	  blood	  and	  stools	  in	  6	  patients.	  	  
Laboratory	  results	  
Immunological	   analysis	   demonstrated	  mild	   alterations	   (i.e.,	   decreased	  percentage	  of	  TCRα/β	  cells,	  low	  B	  or	  T	  cell	  number	  with	  impaired	  PHA)	  in	   few	   patients	   probably	   as	   a	   consequence	   of	   previous	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immunosuppressive	  treatment.	  Hypogammaglobulinemia	  was	  found	  in	  9	   patients;	   2	   subjects	   had	   very	   low/absent	   B	   cells	   but	   no	   BTK	   gene	  mutation	  at	  gene	  analysis.	  	  
IgE	   levels	   were	   increased	   in	   5	   patients.	   Anti	   nuclear	   autoantibodies	  were	  detected	  in	  3	  patients.	  
Treatment	  and	  outcome	  
Total	   parenteral	   nutrition	   was	   necessary	   in	   one	   third	   of	   patients	  because	   of	  malnutrition	   due	   to	   severe	   enteropathy;	   14	   patients	   were	  treated	   with	   immunosuppressive	   drugs	   with	   transient	   clinical	  improvement	   in	   some	   of	   them.	   9	   patients	   received	   IVIG	   for	   both	  substitutive	   therapy	   and	   ITP	   treatment.	   HSCT	   was	   performed	   in	   4	  patients	  and	  they	  are	  all	  doing	  well.	  
In	   this	   cohort	   of	   patients	   one	   died	   at	   3	   years	   old	   because	   of	   severe	  diarrhoea	  and	  another	  one	  died	  when	  he	  was	  18	  because	  of	  sepsis.	  	  	  
Molecular	  Analysis	  
The	  genetic	  analysis	  of	  gene	  related	  to	  IPEX-­‐like	  syndrome	  did	  not	  show	  any	   mutation	   in	   this	   cohort	   of	   subjects.	   CD25,	   STAT5b,	   STAT1	   genes	  were	  studied	  in	  12,	  7	  and	  9	  patients	  respectively,	  but	  all	  resulted	  wild-­‐type.	   One	   patient	   resulted	   heterozygous	   for	   a	   sequence	   variation	   of	  
STAT5b	   was	   found	   and	   functional	   studies	   have	   to	   be	   performed	   to	  investigate	   the	   existence	   of	   a	   correlation	   with	   the	   clinical	  manifestations.	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Multiple	  autoimmunity	  without	  diarrhoea	  
A	   small	   number	   of	   blood	   samples	   came	   from	   patients	   affected	   by	  multiple	  autoimmunity	  that	  present	  at	  least	  two	  autoimmune	  diseases,	  except	   diarrhoea.	   The	   age	   of	   onset	   range	   from	   1	   to	   8	   years	   old.	   The	  main	   symptoms	   at	   onset	   were	   endocrinopathy	   and	   cytopenia.	   IDDM	  was	   present	   in	   4	   patients,	   autoimmune	   thyroidits	   in	   2	   and	   primary	  hypoadrenalism	  in	  2.	  4	  patients	  developed	  ITP,	  neutropenia	  and	  direct	  Coombs	  test	  were	  reported	  in	  2/7	  respectively.	  Cutaneous	  involvement	  included	  atopic	  eczema	  and	  alopecia	  in	  2	  subjects	  respectively.	  3/7	  had	  autoimmune	   hepatitis	   and	   one	   had	   idiopathic	   arthritis.	   Bowel	  involvement	  with	  celiac	  disease	  was	  found	  in	  2	  patients.	  3	  patients	  with	  hypogammaglobulinemia	   suffered	   from	   recurrent	   respiratory	  infections;	   no	   deep	   infections	   were	   reported.	   Organ	   specific	  autoantibodies	  were	  found	  positive	  in	  most	  of	  them.	  The	  patients	  are	  all	  alive	   and	  most	   of	   them	   under	   IVIG,	   steroids	   and	   immunosuppressive	  treatment	  to	  control	  symptoms.	  
Among	   this	   group	   genetic	   analysis	   of	   STAT5b	   was	   performed	   in	   2	  patients	   with	   GH	   deficiency	   and	   consequent	   failure	   to	   thrive;	   STAT1	  was	  studied	   in	  4	  of	   them.	  All	  probands	  carried	  wild	   type	  sequence.	   In	  two	   patients	   with	   hypoadrenalism,	   associated	   respectively	   with	   nails	  dystrophy/retention	   of	   primary	   teeth/infections	   and	  thyroiditis/cytopenia,	   APECED	   (autoimmune	   polyendocrinopathy-­‐candidiasis-­‐ectodermal	  dystrophy)	  was	  excluded	  by	  AIRE	  analysis.	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DISCUSSION	  
	  
Several	   mechanisms	   are	   involved	   in	   the	   maintenance	   of	   immune	  tolerance.	   Treg	   are	   fundamental	   for	   active	   immune	   suppression.	  Different	   types	   of	   Treg	   have	   been	   described	   over	   the	   past	   years	  with	  different	  mechanisms	  of	  action.	  FOXP3	  is	  a	  transcription	  factor	  critical	  for	  the	  development	  and	  function	  of	  CD4+CD25+	  Treg.	  nTreg	  arise	  from	  the	   thymus	  and	  constitutively	  express	  FOXP3	  and	  CD25.	  They	  repress	  lymphocyte	   proliferation	   through	   cell	   contact	   and	   do	   not	   proliferate	  themselves	  [31].	  Inducible	  Treg	  (iTreg)	  generate	  in	  the	  periphery	  from	  CD4	  naïve	   T	   cells	   upon	   stimulation	  with	   IL2	   and	  TGF-­‐beta	   [26].	   They	  transiently	  express	  FOXP3	  and	  exert	  regulatory	  function	  depending	  on	  the	  cytokine	  milieu	  present	  in	  the	  periphery	  after	  antigen	  stimulation	  of	  dendritic	  cells.	  	  	  
IPEX	   syndrome	   is	   a	   X-­‐linked	   recessive	   disease	   caused	   by	   mutations	  within	  the	  FOXP3	  gene.	  Early	  onset	  of	  severe	  diarrhoea,	  failure	  to	  thrive,	  eczematous	   rash	   and	   IDDM	   are	   the	   hallmarks	   of	   this	   syndrome,	   but	  other	   autoimmune	   disorders,	   including	   autoimmune	   cytopenias,	  nephropathy,	  thyroiditis,	  can	  be	  detected	  during	  its	  natural	  course.	  	  
In	   this	   study	   we	   have	   analyzed	   data	   from	   76	   patients	   affected	   by	  complex	  autoimmunity	  resembling	  IPEX	  syndrome	  and	  referred	  to	  the	  NEROFARBA	   Department,	   Section	   of	   Child's	   Health,	   University	   of	  Florence.	   69	   patients	   were	   analyzed	   for	   FOXP3	   mutations:	   16	   were	  found	  to	  have	  molecular	  aberrations	  within	  the	  gene,	  therefore	  affected	  by	   IPEX	   syndrome,	   the	   remaining	   60	   patients	   have	   been	   classified	   as	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IPEX-­‐like.	   Comparing	   the	   two	   cohorts	   of	   patients,	   we	   try	   to	   identify	  indicators	   that	   may	   help	   to	   differentiate	   IPEX	   and	   IPEX-­‐like	   diseases	  and	   consequently	   to	   characterize	   possible	   disease	   sub-­‐groups	   within	  the	   IPEX-­‐like	   cohort	   to	   ultimately	   narrow	   the	   disease	   spectrum	   of	  complex	  autoimmunity	  and	  to	  eventually	  suggest	  new	  genetic	  causes.	  	  
Since	   enteropathy	   is	   the	   unique	   characteristic	   shared	   by	   nearly	   all	  IPEX-­‐like	   patients,	  we	   divided	   IPEX-­‐like	   patients	   in	   two	   groups	   based	  on	   the	   age	   of	   onset	   of	   gut	   disease.	  Based	  on	   the	   fact	   that	  we	   recently	  found	  two	  patients	  with	  an	  atypical	  form	  of	  IPEX-­‐syndrome	  (the	  former	  presented	  bowel	  disease	  at	  11	  years	  old,	  the	  latter	  had	  failure	  to	  thrive	  in	  the	  first	  infancy	  and	  abdominal	  pain	  with	  mild	  diarrhoea	  as	  a	  child),	  we	   also	   included	   in	   the	   study	   another	   small	   group	   of	   patients	  characterized	  by	  multiple	  autoimmunity	  except	  mention	  of	  diarrhoea	  so	  far.	  	  	  	  
Between	   the	   first	   two	   cohorts	   of	   patients,	   histology	   from	  gut	  biopsies	  showed	   results	   compatible	   with	   autoimmune	   enteropathy	   in	   the	  majority	   of	   the	   subjects	  with	   an	   early	   onset,	  mostly	   complicated	   by	   a	  serious	   and	   rapidly	  worsening	  disease	   course.	   Interestingly	   diarrhoea	  was	  the	  main	  symptom	  at	  onset	   in	  all	  patients	  presenting	  early	   in	   life,	  frequently	  associated	  with	  important	  failure	  to	  thrive.	  Compared	  to	  the	  life	  threatening	  diarrhoea	  of	  IPEX	  syndrome,	  the	  course	  of	  diarrhoea	  in	  this	  cohort	  was	  not	  always	  as	  severe:	  in	  some	  patients	  symptoms	  were	  well	  controlled	  by	  immunosuppressive	  treatment,	  others	  had	  a	  mild	  to	  moderate	  diarrhoea	  without	  consequence	  on	  growth	  and	   few	  patients	  recover	  within	  the	  first	  years	  of	  life.	  In	  these	  last,	  we	  can	  postulate	  that	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villous	  atrophy	  is	  the	  result	  of	  breaking	  the	  balance	  between	  microbiota	  and	   immune	   tolerance	   in	   immature	   neonatal	   gut	   with	   consequent	  increased	  susceptibility	  to	  acute	  infectious	  disease.	  On	  the	  other	  hand,	  7	  IPEX-­‐like	  early	  onset	  patients	  required	  HSCT	  as	  unique	  permanent	  cure	  and	  6	  died	  due	  to	  consequence	  of	  intractable	  diarrhoea.	  
In	   the	   second	   cohort	   of	   subjects	   symptoms	   at	   onset	   could	   be	   various	  (infections,	  enteropathy,	   IDDM).	   Intestinal	  bowel	  disease	  and	  common	  variable	  immunodeficiency	  were	  frequently	  taken	  into	  consideration	  as	  possible	   differential	   diagnosis	   because	   of	   delayed	   onset	   diarrhoea	  associated	   with	   chronic	   inflammation	   at	   gut	   biopsy	   in	   one,	   and	  autoimmunity	   (mainly	   cytopenia)	   coupled	   with	  hypogammaglobulinemia	  in	  the	  other.	  	  
As	  hallmark	   signs	   of	   IPEX	   syndrome,	   half	   of	   patients	  with	   early	   onset	  presents	   a	   kind	   of	   eczematous	   rash;	   autoimmune	   skin	   disease	   (i.e.	  alopecia,	   vitiligo)	   are	   otherwise	   prevalent	   in	   subjects	   with	   a	   delayed	  onset	  in	  the	  course	  of	  time.	  	  	  
Endocrinopathy	  seems	  not	  essential	  for	  identifying	  IPEX-­‐like	  syndrome	  because	  it	  is	  equally	  present	  in	  all	  the	  three	  subgroups	  of	  patients.	  
Differently	   autoimmune	   cytopenias	   seem	   to	   be	   predominant	   in	   the	  
FOXP3	  wild	   type	  cohort.	  This	  observation	   is	  not	  surprising	  since	  AIHA	  and	   ITP	   are	   the	   most	   common	   autoimmune	   manifestations	   among	  primary	   immunodeficiency	   disorders	   with	   autoimmune	   features	   in	  general	  [32],	  although	  in	  IPEX-­‐like	  they	  contribute	  to	  define	  the	  clinical	  phenotype	  and	  are	  more	  frequent	  when	  compared	  to	  IPEX	  syndrome.	  	  
Laboratory	  findings	  in	  the	  group	  of	  IPEX	  patients	  showed	  increased	  IgE	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level,	   hypereosinophilia	   and	   positive	   anti-­‐enterocyte	   antibody,	   when	  tested,	  consistently	  with	  the	  literature.	  In	  contrast,	  in	  IPEX	  like	  subjects	  IgE	  were	  found	  increased	  in	  14	  patients	  of	  the	  early	  onset	  group	  versus	  only	  5	  in	  the	  late	  one.	  Regarding	  other	  immunological	  indices,	  only	  few	  IPEX-­‐like	   patients	   had	   positive	   organ-­‐specific	   autoantibody	  with	   poor	  clinical	   correlation.	   Mild	   impairment	   of	   lymphocyte	   count	   was	  sometime	   reported,	   mostly	   in	   relation	   to	   heavy	   immunosuppressive	  treatment.	   Accordingly	   these	   patients	   had	   a	   significantly	   increased	  susceptibility	   to	   bacterial	   and	   viral	   infections.	   In	   patients	   with	   early	  diarrhoea	  onset	  it	  is	  reasonably	  postulated	  that	  severe	  infections	  could	  be	  also	  a	  consequence	  of	  decreased	  barrier	  function	  of	  the	  gut.	  	  
In	   the	   IPEX-­‐like	   cohort	   genetic	   analysis	   was	   addressed	   to	   identify	  mutations	   in	   genes	   actually	   known	   to	   be	   involved	   in	   FOXP3	  pathway.	  Studies	   were	   driven	   by	   clinical	   presentation,	   according	   to	   what	  described	  in	  literature.	  	  
It	  is	  remarkable	  that	  affected	  patients	  presented	  symptoms	  within	  few	  months	   of	   life.	   CD25	   was	   found	   mutated	   in	   3	   patients	   with	   watery	  diarrhoea,	   villous	   atrophy	   and	   eczema	   started	   at	   one	   months	   of	   age	  with	  no	  expression	  of	  CD25	  at	   flow	  cytometry,	   and	  a	  STAT1	  mutation	  was	   identified	   in	  a	  patient	  deceased	  at	   four	  years	  of	  age	   for	  aneurysm	  rupture	  [table	  IIIa,	  IIIb].	  
Interestingly,	   recently	   we	   investigated	   the	   follow	   up	   of	   IPEX-­‐like	  patients	   and	   we	   learnt	   about	   three	   new	   diagnosis	   of	   novel	   primary	  immunodeficiencies	   made	   by	   the	   referring	   centres.	   Two	   Pakistani	  brothers	   with	   early	   onset	   diarrhoea,	   recurrent	   severe	   respiratory	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infections,	   perianal	   abscesses,	   hepatosplenomegaly	   and	   impaired	  response	  to	  LPS,	  were	  found	  to	  have	  a	  mutation	  in	  a	  gene	  that	  encodes	  for	   a	   key	   integrator	   of	   signaling	   pathways	   initiated	   by	   stimulation	   of	  death	  receptors,	  bacterial	  or	  viral	  infections,	  genotoxic	  stress	  and	  T-­‐cell	  homeostasis.	  Further	  studies	  are	  still	  ongoing	  to	  better	  characterize	  the	  gene	  defect.	  Exome	  sequencing	  performed	  in	  a	  6	  years	  old	  Slovenian	  girl	  with	  mild	  eczema,	  diarrhoea	  with	  EBV	  in	  gut,	  bacterial	  sepsis	  and	  viral	  infections,	  facial	   dysmorfism	   and	   psychomotor	   delay,	   showed	   a	   mutation	   in	  another	  gene	  involved	  in	  activating	  nuclear	  factor-­‐κB	  (NF-­‐κB)	  response	  in	  antigen-­‐stimulated	  lymphocytes.	  	  NF-­‐κB	  signaling	  plays	  a	  key	  role	  in	  inflammation	   and	   immunity.	   This	   mutation	   was	   not	   previously	  described	   and	   the	   Slovenian	   group	   is	   actually	   performing	   functional	  tests	  to	  understand	  the	  importance	  of	  the	  sequence	  mutated.	  
Finally,	   lipopolysaccharide	   responsive	   beige-­‐like	   anchor	   (LRBA)	   gene	  mutation	   was	   detected	   by	   exome	   sequencing	   in	   a	   Turkish	   girl	   with	  delayed	   onset	   severe	   diarrhoea,	   autoimmune	   endocrinopathy	   and	  cytopenia.	   LRBA	   deficiency	   has	   been	   recently	   described	   as	   a	   novel	  immunodeficiency	   characterized	   by	   features	   of	   CVID,	   immune	  dysregulation,	   or	   both	  manifesting	   as	   early	   onset	   colitis	   with	   chronic	  diarrhoea	  and	  autoimmunity;	  additional	  reports	  and	  long	  term	  follow-­‐up	  will	  delineate	  the	  full	  phenotypic	  spectrum	  of	  this	  disease	  [33,	  34].	  
Giving	  the	  broad	  clinical	  spectrum	  of	  complex	  autoimmune	  diseases,	  it	  is	   intriguing	   to	   postulate	   that	   other	   regulatory	   mechanisms	   different	  than	  CD4+CD25+FOXP3+	   regulatory	  T	   cells,	   impaired	   in	   IPEX	  disease,	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could	   contribute	   in	   modulating	   IPEX	   disease	   course	   and	   determining	  IPEX-­‐like	   phenotypes.	   In	   particular,	   a	   defective	   interaction	   within	  antigen	   presenting	   cells	   and	   CD4	   naive	   T	   lymphocytes	   could	   cause	  alteration	   in	   T	   cell	   commitment	   and	   peripheral	   tolerance	   and	  mechanism	  impairing	  signaling	  for	  apoptosis	  could	  lead	  to	  autoimmune	  and	  autoinflammatory	  conditions.	  	  
In	  summary	  this	  study	  shows	  that,	  among	  subjects	  with	  clinical	  features	  of	  congenital/inherited	  immune	  dysregulation	  where	  IPEX	  is	  ruled	  out,	  we	  could	  identify	  three	  distinct	  groups.	  The	  first	  one	  is	  the	  “true”	  IPEX-­‐like	  group,	  which	  comprises	  patients	  with	  severe	  early	  onset	  diarrhoea	  associated	  with	   other	   autoimmune	  manifestations	   (behaving	   similarly	  to	  the	  IPEX	  cohort	   in	  terms	  of	  clinical	  and	   immunological	   features).	   In	  those	   will	   be	   mandatory	   to	   study	   FOXP3	   signaling	   pathway	   and	  eventually	  to	  analyze	  other	  genes	  involved	  in	  immune	  regulation	  (CD25,	  
STAT5b,	   STAT1).	   The	   second	   group	   consists	   of	   patients	   affected	   by	  multiple	   autoimmune	   diseases:	   patients	   with	   delayed	   onset	   of	   more	  than	   2	   autoimmune	   manifestations.	   Immunological	   work	   up	   will	   be	  essential	   to	  exclude	  a	  combined	  primary	   immunodeficiency	  or	  a	  B	  cell	  disease	  (features	  often	  overlap	  with	  CVID,	  LRBA	  deficiency,	  ALPS,	  Omen	  Syndrome,	   DGS,	   etc.)	   or	   to	   contribute	   to	   address	   further	   genetic	  analysis.	   The	   third	   one	   includes	   subjects	   with	   immune-­‐mediated	  enteropathy	   with	   no	   other	   symptoms	   associated,	   except	   perianal	  abscesses	  or	  enteric	  fistula.	  In	  these	  cases	  the	  presence	  of	  IL10,	  IL10RA,	  
IL10RB	  gene	  mutations	  should	  be	  excluded	  and	  gut	  biopsy	  will	  help	  to	  explain	  pathogenesis	  (Innate	  immunity?	  IBD-­‐like?).	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In	  conclusion	  this	  preliminary	  study	  highlights	  the	  importance	  of	  severe	  autoimmune	   enteropathy	   as	   key	   clinical	   marker	   of	  immunedysregulation.	  
In	   addition,	   genetic	   analysis	   for	   FOXP3	   mutations	   should	   always	   be	  performed	   in	   male	   patients	   with	   symptoms	   indicative	   of	   IPEX	  syndrome,	   and	   in	   case	   of	   normal	   FOXP3,	   the	   other	   genes	   involved	   in	  FOXP3	   function	   (i.e.	   CD25	   STAT5b)	   and,	   in	   selected	   patients,	   STAT1,	  
IL10,	   IL10RA-­RB,	   should	   also	   be	   considered	   if	   the	   phenotype	   is	  suggestive.	   Flow	   cytometry	   could	   be	   essential	   to	   address	   analysis	   of	  
CD25	  when	  the	  expression	  is	  absent	  [Fig.3]	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TABLE I: Molecular analysis. Among 113 patients analysed, only 76 had clinical 
presentations and laboratory results consistent with IPEX Syndrome. 	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TABLE IIIa. Comparison between clinical characteristics of IPEX-like patients with CD25 
deficiency reported in literature. Our group of research identified the CD25 gene mutation in pt 3.  
 
	   Pt	  1	  
(Sharfe	  N	  et	  al.	  [13])	  
Pt	  2	  
(Caudy	  et	  al.[14])	  
Pt	  3	  
	  (OUR	  PATIENT)	  
(Goudy	  K	  et	  al.[16])	  Initial	  	  presentation	   Infancy	   Infancy	   Infancy	  Sex	   Male	   Male	   Female	  Outcome	   Alive	   Alive	   Alive	  
Enteropathy	   Chronic	  diarrhoea	   	   Severe	  diarrhoea	  (protein	  losing	  enteropathy)	  Gut	  biopsy:	  villous	  atrophy,	  CMV	  pos	  
Severe	  diarrhoea	  	  Gut	  biopsy:	  villous	  atrophy,	  CMV	  pos	  
Skin	   None	   Diffuse	  eczema	   Diffuse	  eczema	  Bollous	  pemphigoid	  Alopecia	  universalis	  Infections	   Bacterial	  infections	  Persistent	  oral	  trush	  Candida	  esophagitis	  Chronic	  lung	  disease	  
Persistent	  sinusitis	  Recurrent	  otitis	  Recurrent	  pneumonias	  	  
Cellulitis	  caused	  by	  Staphilococcus	  Au.	  Pseudomonas	  Ae	  
Herpes	  Infections	   CMV	  pneumonitis	   CMV	  in	  gut/blood	  EBV	  in	  lymphonode	  CMV	  pneumonitis	   CMV	  in	  gut/blood	  Endocrine	   None	   Hypothiroidism	   Hypothiroidism	  Growth	   Failure	  to	  thrive	   Failure	  to	  thrive	   Failure	  to	  thrive	  
Hematology	   Iron	  deficiency	  anemia	   	   AIHA	  Neutropenia	   None	  Others	   Lymphadenopathy	  hepatosplenomegaly	   Lymphadenopathy	  hepatosplenomegaly	   Lymphadenopathy	  	  Laboratory	  Results	   Increased	  IgG	  levels	  Low	  IgA	  Low	  CD3+CD4+	  cells	  Absent	  CD25	  expression	  
Increased	  IgG	  levels	  Absent	  CD25	  expression	   Increased	  IgE	   	  Absent	  CD25	  expression	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TABLE IIIb. Comparison between clinical characteristic of IPEX-like patients with STAT1 mutation 



















	   36	  
















	   37	  
REFERENCES	  
	  
1.	  Powell	  BR,	  Buist	  NR,	  Stenzel	  P.	  An	  X-­‐linked	  syndrome	  of	  diarrhoea,	  poly-­‐endocrinopathy,	   and	   fatal	   infection	   in	   infancy.	   J	   Pediatr	  1982;100:731–7.	  
2.	   Bennett	   CL,	   Ochs	   HD.	   IPEX	   is	   a	   unique	   X-­‐linked	   syndrome	  characterized	   by	   immune	   disfunction,	   polyendocrinopathy,	  enteropathy,	   and	   a	   variety	   of	   autoimmune	   phenomena.	   Curr	   Opin	  Pediatr.	  2001;13:533–8.	  
3.	  Gambineri	  E,	  Perroni	  L,	  Passerini	  L,	  Bianchi	  L,	  Doglioni	  C,	  Meschi	  F,	  et	  al.	   Clinical	   and	   molecular	   profile	   of	   a	   new	   series	   of	   patients	   with	  immune	   dysregulation,	   polyendocrinopathy,	   enteropathy,	   X-­‐linked	  syndrome:	   Inconsistent	   correlation	   between	   forkhead	   box	   protein	   3	  expression	   and	   disease	   severity.	   J	   Allergy	   Clin	   Immunol.	  2008;122:1105-­‐2.	  
4.	  Notarangelo	  LD,	  Gambineri	  E,	  Badolato	  R.	   Immunodeficiencies	  with	  autoimmune	  consequences.	  Adv	  Immunol	  2006;89:321–70.	  
5.	  Torgerson	  TR,	  Ochs	  HD.	  Immune	  dysregulation,	  polyendocrinopathy,	  enteropathy,	   X-­‐linked:	   forkhead	   box	   protein	   3	   mutations	   and	   lack	   of	  regulatory	  T	  cells.	  J	  Allergy	  Clin	  Immunol	  2007;120:744–50.	  	  
6.	  Ochs	  HD,	  Ziegler	   SF,	  Torgerson	  TR.	  FOXP3	  acts	   as	   a	   rheostat	  of	   the	  immune	  response.	  Immunol	  Rev	  2005;203:156–64.	  	  
7.	  Wildin	  RS,	  Ramsdell	  F,	  Peake	  J,	  Faravelli	  F,	  Casanova	  JL,	  Buist	  N,	  et	  al.	  X-­‐linked	   neonatal	   diabetes	   mellitus,	   enteropathy	   and	   endocrinopathy	  
	   38	  
syndrome	   is	   the	   human	   equivalent	   of	   mouse	   scurfy.	   Nat	   Genet	  2001;27:18-­‐20.	  
8.	  Passerini	  L,	  Olek	  S,	  Di	  Nunzio	  S,	  Barzaghi	  F,	  Hambleton	  S,	  Abinun	  M,	  et	   al.	   Forkhead	   box	   protein	   3	   (FOXP3)	   mutations	   lead	   to	   increased	  TH17	   cell	   numbers	   and	   regulatory	   T-­‐cell	   instability.	   J	   Allergy	   Clin	  Immunol.	  2011;128(6):1376-­‐1379.e1371.	  
9.	  Bindl	  L,	  Torgerson	  T,	  Perroni	  L,	  Youssef	  N,	  Ochs	  HD,	  Goulet	  O,	  et	  al.	  Successful	   use	   of	   the	   new	   immune-­‐suppressor	   sirolimus	   in	   IPEX	  (immune	   dysregulation,	   polyendocrinopathy,	   enteropathy,	   X-­‐linked	  syndrome).	  J	  Pediatr	  2005;147:256–9.	  
10.	   Mazzolari	   E,	   Forino	   C,	   Fontana	   M,	   D'Ippolito	   C,	   Lanfranchi	   A,	  Gambineri	   E,	   et	   al.	   A	   new	   case	   of	   IPEX	   receiving	   bone	   marrow	  transplantation.	  Bone	  Marrow	  Transplant	  2005;35:1033–4.	  
11.	   Rao	   A,	   Kamani	   N,	   Filipovich	   A,	   Lee	   SM,	   Davies	   SM,	   Dalal	   J	   et	   al.	  Successful	   bone	   marrow	   transplantation	   for	   IPEX	   syndrome	   after	  reduced-­‐intensity	  conditioning.	  Blood	  2007;109:383.	  12.	  Zorn	  E,	  Nelson	  EA,	  Mohseni	  M,	  Porcheray	  F,	  Kim	  H,	  Litsa	  D,	  et	  al.	  IL-­‐2	  regulates	  FOXP3	  expression	  in	  human	  CD4+CD25+	  regulatory	  T	  cells	  through	   a	   STAT-­‐dependent	   mechanism	   and	   induces	   the	   expansion	   of	  these	  cells	  in	  vivo,	  Blood	  2006;108:1571–1579.	  
13.	  Sharfe	  N,	  Dadi	  HK,	  Shahar	  M,	  Roifman	  CS.	  Human	  immune	  disorder	  arising	  from	  mutation	  of	   the	  alpha	  chain	  of	   the	   interleukin-­‐2	  receptor.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  1997;94:3168–71.	  
14.	   Caudy	   AA,	   Reddy	   ST,	   Chatila	   T,	   Atkinson	   JP,	   Verbsky	   JW.	   CD25	  deficiency	   causes	   an	   immune	   dysregulation,	   polyendocrinopathy,	  
	   39	  
enteropathy,	   X-­‐linked-­‐like	   syndrome,	   and	   defective	   IL-­‐10	   expression	  from	  CD4	  lymphocytes.	  J	  Allergy	  Clin	  Immunol	  2007;119:482–7.	  
15.	   Roifman	   CM.	  Human	   IL-­‐2	   receptor	   alpha	   chain	   deficiency.	   Pediatr	  Res	  2000;48:6–11.	  
16.	   Goudy	   K,	   Aydin	   D,	   Barzaghi	   F,	   Gambineri	   E,	   Vignoli	   M,	   Ciullini	  Mannurita	   S,	   et	   al. Human	   IL2RA	   null	   mutation	   mediates	  immunodeficiency	   with	   lymphoproliferation	   and	   autoimmunity.	   Clin	  Immunol.	   2013	   Mar;146(3):248-­‐61.	   doi:	   10.1016/j.clim.2013.01.004.	  Epub	  2013	  Jan	  24.	  
17.	   Liu	   X,	   Robinson	   GW,	   Wagner	   KU,	   Garrett	   L,	   Wynshaw-­‐Boris	   A,	  Hennighausen	   L.	   et	   al.	   Stat5a	   is	  mandatory	   for	   adult	  mammary	   gland	  development	  and	  lactogenesis.	  Genes	  Dev.	  1997;11:179–86	  
18.	  Nadeau	  K,	  Hwa	  V,	  Rosenfeld	  RG.	  STAT5b	  deficiency:	  an	  unsuspected	  cause	   of	   growth	   failure,	   immunodeficiency,	   and	   severe	   pulmonary	  disease.	  J.	  Pediatr.	  2011;158:701–08.	  
19.	   Burchill	   MA,	   Yang	   J,	   Vogtenhuber	   C,	   Blazar	   BR,	   Farrar	   MA.	   IL-­‐2	  receptor	   beta-­‐dependent	   STAT5	   activation	   is	   required	   for	   the	  development	  of	  Foxp3þ	  regulatory	  T	  cells.	  J	  Immunol	  2007;178:280–90.	  
20.	  Yao	  Z,	  Kanno	  Y,	  Kerenyi	  M,	  Stephens	  G,	  Durant	  L,	  Watford	  WT,	  et	  al.	  Nonredundant	   roles	   for	   Stat5a/b	   in	   directly	   regulating	   Foxp3.	   Blood	  2007;109:4368–75.	  
21.	  Bernasconi	  A,	  Marino	  R,	  Ribas	  A,	  Rossi	  J,	  Ciaccio	  M,	  Oleastro	  M,	  et	  al.	  Characterization	   of	   immunodeficiency	   in	   a	   patient	   with	   growth	  hormone	   insensitivity	   secondary	   to	   a	   novel	   STAT5b	   gene	   mutation.	  
	   40	  
Pediatrics	  2006;118:e1584–92.	  
22.	   Hwa	   V,	   Little	   B,	   Adiyaman	   P,	   Kofoed	   EM,	   Pratt	   KL,	   Ocal	   G, et	   al.	  Severe	   growth	   hormone	   insensitivity	   resulting	   from	   total	   absence	   of	  signal	   transducer	   and	   activator	   of	   transcription	   5b.	   J	   Clin	   Endocrinol	  Metab	  2005;90:4260–6.	  	  
23.	  Kofoed	  EM,	  Hwa	  V,	  Little	  B,	  Woods	  KA,	  Buckway	  CK,	  Tsubaki	  J,	  et	  al.	  Growth	   hormone	   insensitivity	   associated	   with	   a	   STAT5b	  mutation.	   N	  Engl	  J	  Med	  2003;	  349:1139–47.	  21.	  	  
24.	   Cohen	  AC,	  Nadeau	  KC,	   Tu	  W,	  Hwa	  V,	   Dionis	   K,	   Bezrodnik	   L,	   et	   al.	  Cutting	  edge:	  Decreased	  accumulation	  and	  regulatory	  function	  of	  CD4+	  CD25(high)	   T	   cells	   in	   human	   STAT5b	   deficiency.	   J	   Immunol	  2006;177(5):2770–4.	  
25.	  Yao	  Z,	  Cui	  Y,	  Watford	  WT,	  Bream	  JH,	  Yamaoka	  K,	  Hissong	  BD,	  et	  al.	  Stat5a/b	   are	   essential	   for	   normal	   lymphoid	   development	   and	  differentiation.	  Proc.	  Natl.	  Acad.	  Sci.	  USA	  2006;103:	  1000-­‐5.	  	  
26.	  Roncarolo	  MG,	  Gregori	  S,	  Battaglia	  M,	  Bacchetta	  R,	  Fleischhauer	  K,	  Levings	   MK.	   Interleukin-­‐10-­‐secreting	   type	   1	   regulatory	   T	   cells	   in	  rodents	  and	  humans.	  Immunol	  Rev.	  2006	  Aug;212:28-­‐50	  
27.	  Glocker	  EO,	  Kotlarz	  D,	  Boztug	  K,	  Gertz	  EM,	  Schäffer	  AA,	  Noyan	  F,	  et	  al.	  Inflammatory	  bowel	  disease	  and	  mutations	  affecting	  the	  interleukin-­‐10	  receptor.	  N	  Engl	  J	  Med.	  2009	  Nov	  19;361(21):2033-­‐45.	  	  
28.	  Uzel	  G,	  Sampaio	  EP,	  Lawrence	  MG,	  Hsu	  AP,	  Hackett	  M,	  Dorsey	  MJ,	  et	  al.	   Dominant	   gain-­‐of-­‐function	   STAT1	   mutations	   in	   FOXP3	   wild-­‐type	  immune	   dysregulation–polyendocrinopathy–enteropathy–X-­‐linked–
	   41	  
like	  syndrome.	  J	  Allergy	  Clin	  Immunol.	  2013	  Jun;131(6):1611-­‐23.	  	  
29.	  Huehn	   J,	   Polansky	   Jk	   and	  Hamann	  A.	   Epigenetic	   control	   of	   FOXP3	  expression:	   the	   key	   to	   a	   stable	   regulatory	   T-­‐cell	   lineage?	   Nat	   Rev	  Immunol.	  2009	  Feb;9(2):83-­‐9.	  	  
30.	   Patey-­‐Mariaud	   de	   Serre,	   Canioni	   D,	   Ganousse	   S,	   Rieux-­‐Laucat	   F,	  Goulet	  O,	  Ruemmele	  F	  et	  al.	  Digestive	  histopathological	  presentation	  of	  IPEX	  syndrome.	  Modern	  Pathol	  2009;22:95-­‐102	  
31.	  Zhu	  J,	  Yamane	  H	  and	  Paul	  WE.	  Differentiation	  of	  effector	  CD4	  T	  cell	  populations.	  Annu	  Rev	  Immunol	  2010;	  28:445-­‐89.	  	  
32.	   Cunningham-­‐Rundles	   C.	   Hematologic	   complications	   of	   primary	  immune	  deficiencies.	  Blood	  Rev	  2002,	  16:61–64.	  
33.	  	  Alangari	  A,	  Alsultan	  A,	  Adly	  N,	  Massaad	  MJ,	  Kiani	  IS,	  Aljebreen	  A,	  et	  al.	  LPS-­‐responsive	  beige-­‐like	  anchor	  (LRBA)	  gene	  mutation	   in	  a	   family	  with	   inflammatory	   bowel	   disease	   and	   combined	   immunodeficiency.	   J	  Allergy	  Clin	  Immunol.	  2012	  Aug;130(2):481-­‐8.e2.	  	  
34.	   Lopez-­‐Herrera	   G,	   Tampella	   G,	   Pan-­‐Hammarström	   Q,	   Herholz	   P,	  Trujillo-­‐Vargas	  CM,	  Phadwal	  K	  et	  al.	  Deleterious	  mutations	  in	  LRBA	  are	  associated	  with	   a	   syndrome	   of	   immune	   deficiency	   and	   autoimmunity.	  Am	  J	  Hum	  Genet.	  2012	  Jun	  8;90(6):986-­‐1001.	  
